# Pembrolizumab, Ibrutinib and Rituximab in PCNSL

> **NCT04421560** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 37 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma
- Recurrent Cancer
- Refractory Cancer
- Relapsed Cancer

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Pembrolizumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04421560
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-01
- **Primary completion:** 2026-12-05
- **Final completion:** 2027-01-05
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421560, "Pembrolizumab, Ibrutinib and Rituximab in PCNSL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04421560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*